The effect of pegylated interferon-α on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection

Journal of Hepatology

Volumn 44, Issue 3, 2006, Pages 507-511

  Leemans, Wilhelmus F ^a   Flink, Hajo J ^a   Janssen, Harry L A ^a   Niesters, Hubert G M ^a   Schalm, Solko W ^a   De Man, Robert A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

HBeAg positive; Hepatitis B virus; Lamivudine; PEG interferon; Resistance; YMDD

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS E ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2B; TETRAPEPTIDE; TYROSYLMETHIONYLASPARTYLASPARTATE; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COURSE EVALUATION; DRUG EFFICACY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN MOTIF; REBOUND; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VIRUS LOAD; VIRUS MUTATION; VIRUS TITRATION;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG CARRIERS; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; LAMIVUDINE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 32444450074     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2005.12.004     Document Type: Article

References (27)

1. F.V. Chisari, and C. Ferrari Hepatitis B virus immunopathogenesis Annu Rev Immunol 13 1995 29 60
2. A. Pariente, A. Tachet, and J.D. Poveda Treatment of lamiduvine-resistant mutant chronic hepatitis B with interferon alpha Gastroenterol Clin Biol 26 2002 1059 1060
3. A. Danalioglu, S. Kaymakoglu, Y. Cakaloglu, K. Demir, C. Karaca, and Z. Durakoglu Efficacy of alpha interferon therapy for lamivudine resistance in chronic hepatitis B Int J Clin Pract 58 2004 659 661
4. G. Ersoz, U.S. Akarca, F. Gunsar, Z. Karasu, and Y. Batur Interferon re-treatment for resistance to lamivudine plus interferon treatment Turk J Gastroenterol 14 2003 223 227
5. F. Suzuki, A. Tsubota, N. Akuta, T. Someya, M. Kobayashi, and Y. Suzuki Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy J Gastroenterol 37 2002 922 927
6. C.L. Lai, R.N. Chien, N.W. Leung, T.T. Chang, R. Guan, and D.I. Tai A one-year trial of lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group N Engl J Med 339 1998 61 68
7. J.L. Dienstag, E.R. Schiff, T.L. Wright, R.P. Perrillo, H.W. Hann, and Z. Goodman Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 341 1999 1256 1263
8. G. Barbaro, F. Zechini, A.M. Pellicelli, R. Francavilla, G. Scotto, and D. Bacca Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial J Hepatol 35 2001 406 411
9. Y.F. Liaw Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B J Gastroenterol Hepatol 17 2002 S333 S337
10. Y.F. Liaw, N.W. Leung, T.T. Chang, R. Guan, D.I. Tai, and K.Y. Ng Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia hepatitis lamivudine study group Gastroenterology 119 2000 172 180
11. N.W. Leung, C.L. Lai, T.T. Chang, R. Guan, C.M. Lee, and K.Y. Ng Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy Hepatology 33 2001 1527 1532
12. T.T. Chang, C.L. Lai, R.N. Chien, R. Guan, S.G. Lim, and C.M. Lee Four years of lamivudine treatment in Chinese patients with chronic hepatitis B J Gastroenterol Hepatol 19 2004 1276 1282
13. R. de Franchis, A. Hadengue, G. Lau, D. Lavanchy, A. Lok, and N. McIntyre EASL international consensus conference on hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version) J Hepatol 39 2003 S3 S25
14. H.L. Janssen, M. van Zonneveld, H. Senturk, S. Zeuzem, U.S. Akarca, and Y. Cakaloglu Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 2005 123 129
15. K.H. Heermann, W.H. Gerlich, M. Chudy, S. Schaefer, and R. Thomssen Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. Eurohep pathobiology group J Clin Microbiol 37 1999 68 73
16. S.D. Pas, E. Fries, R.A. De Man, A.D. Osterhaus, and H.G. Niesters Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays J Clin Microbiol 38 2000 2897 2901
17. G. Cooksley The treatment of hepatitis B e antigen-positive chronic hepatitis B with pegylated interferon J Hepatol 39 2003 S143 S145
18. G.K. Lau, T. Piratvisuth, K.X. Luo, P. Marcellin, S. Thongsawat, and G. Cooksley Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2005 2682 2695
19. H.L. Janssen, H.J. Flink, M. Zonneveld, H.G. Niesters, R.A. De Man, and S.W Schalm HBsAg seroconversion in chronic HBV patients treated with pegylated interferon alpha-2b alone or in combination with lamivudine. The role of HBV genotype Hepatology 40 2002 660A
20. C.T. Wai, C.J. Chu, M. Hussain, and A.S. Lok HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C Hepatology 36 2002 1425 1430
21. J.H. Kao, P.J. Chen, M.Y. Lai, and D.S. Chen Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B Gastroenterology 118 2002 554 559
22. J.H. Kao, N.H. Wu, P.J. Chen, M.Y. Lai, and D.S. Chen Hepatitis B genotypes and the response to interferon therapy J Hepatol 33 2000 998 1002
23. W.G. Cooksley, T. Piratvisuth, S.D. Lee, V. Mahachai, Y.C. Chao, and T. Tanwandee Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B J Viral Hepat 10 2002 298 305
24. C.L. Lin, S.L. Tsai, T.H. Lee, R.N. Chien, S.K. Liao, and Y.F. Liaw High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B Gut 54 2005 152 161
25. R. Perrillo, H.W. Hann, D. Mutimer, D. Lavanchy, A. Lok, and N. McIntyre Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus Gastroenterology 126 2004 81 90
26. S. Levine, D. Hernandez, G. Yamanaka, S. Zhang, R. Rose, and S. Weinheimer Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro Antimicrob Agents Chemother 46 2002 2525 2532
27. M. Sherman, C. Yurdaydin, J. Sollano, M. Silva, Z. Goodman, and L. Chen Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory, HBeAg(+) chronic hepatitis B: results of phase III study ETV-026 Hepatology 40 2004 664A